SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056965
Filing Date
2024-05-09
Accepted
2024-05-09 16:11:52
Documents
51
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-20240331.htm   iXBRL 10-Q 1258412
2 EX-10.1 lrmr-ex10_1.htm EX-10.1 312313
3 EX-31.1 lrmr-ex31_1.htm EX-31.1 10403
4 EX-31.2 lrmr-ex31_2.htm EX-31.2 10499
5 EX-32.1 lrmr-ex32_1.htm EX-32.1 16028
  Complete submission text file 0000950170-24-056965.txt   6498893

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20240331.xsd EX-101.SCH 903646
55 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20240331_htm.xml XML 1139279
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 24930721
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)